Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 3/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.38 |
| ▸ | UCHL1 | P09936 | 2/20 | 0.38 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.38 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 3/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | PDE4A | P27815 | 1/20 | 0.37 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.37 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.37 |
| ▸ | PARP1 | P09874 | 1/20 | 0.36 |
| ▸ | HTR1A | P08908 | 1/20 | 0.36 |
| ▸ | DRD1 | P21728 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL51067 | 1.00 | HSD11B1 (0.39) | HSD11B1NPC1PDE4BUCHL1NR1H2 | |
| SCHEMBL21255627 | 1.00 | HSD11B1 (0.39) | HSD11B1NPC1PDE4BUCHL1NR1H2 | |
| SCHEMBL50764 | 1.00 | HSD11B1 (0.39) | HSD11B1NPC1PDE4BUCHL1NR1H2 | |
| SCHEMBL50763 | 1.00 | HSD11B1 (0.39) | HSD11B1NPC1PDE4BUCHL1NR1H2 | |
| SCHEMBL15382598 | 1.00 | HSD11B1 (0.39) | HSD11B1NPC1PDE4BUCHL1NR1H2 | |
| SCHEMBL7901664 | 0.90 | DRD2 (0.39) | HSD11B1DRD2PARP1HTR1ADRD1 | |
| SCHEMBL8057860 | 0.89 | LMNA (0.44) | HSD11B1NPC1UCHL1NR1H2NR1H3 | |
| SCHEMBL8068216 | 0.89 | LMNA (0.44) | HSD11B1NPC1UCHL1NR1H2NR1H3 | |
| SCHEMBL10034503 | 0.89 | LMNA (0.44) | HSD11B1NPC1UCHL1NR1H2NR1H3 | |
| SCHEMBL7901592 | 0.87 | HSD11B1 (0.41) | HSD11B1DRD2PARP1HTR1ADRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3653210-A1 | TREATMENT OF DYSKINESIA RELATED DISORDERS | H. Lundbeck A/S (DK) | 2020-05-20 | — | — | EP | disclosed |
| EP-3653210-A1 | TREATMENT OF DYSKINESIA RELATED DISORDERS | H. Lundbeck A/S (DK) | 2020-05-20 | — | — | EP | disclosed |
| EP-2400967-B1 | TREATMENT OF DYSKINESIA RELATED DISORDERS | H LUNDBECK AS (DK) | 2019-08-14 | — | — | EP | disclosed |
| EP-3009437-A1 | A CATECHOLAMINE DERIVATIVE USEFUL FOR THE TREATMENT OF PARKINSON'S DISEASE | H. Lundbeck A/S (DK) | 2016-04-20 | — | — | EP | disclosed |
| EP-2197883-B1 | Catecholamine derivative useful for the treatment of parkinson's disease | LUNDBECK & CO AS H (DK) | 2015-11-18 | — | — | EP | disclosed |
| EP-2662358-A1 | Catecholamine derivatives and prodrugs thereof | H. Lundbeck A/S (DK) | 2013-11-13 | — | — | EP | disclosed |
| US-20120108624-A1 | TREATMENT OF DYSKINESIA RELATED DISORDERS | H. LUNDBECK A/S (DK) | 2012-05-03 | — | — | US | disclosed |
| US-20120108624-A1 | TREATMENT OF DYSKINESIA RELATED DISORDERS | H. LUNDBECK A/S (DK) | 2012-05-03 | — | — | US | disclosed |
| US-20120077836-A1 | METHODS OF ADMINISTERING (4AR,10AR)-1-N-PROPYL-1,2,3,4,4A,5,10,10A-OCTAHYDROBENZO [G] QUINOLINE-6,7-DIOL AND RELATED COMPOUNDS ACROSS THE ORAL MUCOSA, THE NASAL MUCOSA OR THE SKIN AND PHARMACEUTICAL COMPOSITIONS THEREOF | H. LUNDBECK A/S (DK) | 2012-03-29 | — | — | US | disclosed |
| US-20120077836-A1 | METHODS OF ADMINISTERING (4AR,10AR)-1-N-PROPYL-1,2,3,4,4A,5,10,10A-OCTAHYDROBENZO [G] QUINOLINE-6,7-DIOL AND RELATED COMPOUNDS ACROSS THE ORAL MUCOSA, THE NASAL MUCOSA OR THE SKIN AND PHARMACEUTICAL COMPOSITIONS THEREOF | H. LUNDBECK A/S (DK) | 2012-03-29 | — | — | US | disclosed |
| US-8129530-B2 | Catecholamine derivatives and prodrugs thereof | H. LUNDBECK A/S (DK) | 2012-03-06 | — | — | US | disclosed |
| US-8129530-B2 | Catecholamine derivatives and prodrugs thereof | H. LUNDBECK A/S (DK) | 2012-03-06 | — | — | US | disclosed |
| US-8129530-B2 | Catecholamine derivatives and prodrugs thereof | H. LUNDBECK A/S (DK) | 2012-03-06 | — | — | US | disclosed |
| US-20090124651-A1 | CATECHOLAMINE DERIVATIVES AND PRODRUGS THEREOF | H. LUNDBECK A/S (DK) | 2009-05-14 | — | — | US | disclosed |
| US-20090124651-A1 | CATECHOLAMINE DERIVATIVES AND PRODRUGS THEREOF | H. LUNDBECK A/S (DK) | 2009-05-14 | — | — | US | disclosed |
| US-20090124651-A1 | CATECHOLAMINE DERIVATIVES AND PRODRUGS THEREOF | H. LUNDBECK A/S (DK) | 2009-05-14 | — | — | US | disclosed |
| US-20090062324-A1 | CATECHOLAMINE DERIVATIVES AND PRODRUGS THEREOF | H. LUNDBECK A/S (DK) | 2009-03-05 | — | — | US | disclosed |
| US-20090062324-A1 | CATECHOLAMINE DERIVATIVES AND PRODRUGS THEREOF | H. LUNDBECK A/S (DK) | 2009-03-05 | — | — | US | disclosed |
| US-20090062324-A1 | CATECHOLAMINE DERIVATIVES AND PRODRUGS THEREOF | H. LUNDBECK A/S (DK) | 2009-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077836-A1 | METHODS OF ADMINISTERING (4AR,10AR)-1-N-PROPYL-1,2,3,4,4A,5,10,10A-OCTAHYDROBENZO [G] QUINOLINE-6,7-DIOL AND RELATED COMPOUNDS ACROSS THE ORAL MUCOSA, THE NASAL MUCOSA OR THE SKIN AND PHARMACEUTICAL COMPOSITIONS THEREOF | PARK7, SNCA, OPRD1 | HSD11B1 383/4885NPC1 425/4885PDE4B 776/4885 |
| US-20090124651-A1 | CATECHOLAMINE DERIVATIVES AND PRODRUGS THEREOF | COMT, ADRB3, ADRB1 | HSD11B1 129/4885NPC1 750/4885PDE4B 81/4885 |
| US-20090062324-A1 | CATECHOLAMINE DERIVATIVES AND PRODRUGS THEREOF | COMT, ADRB3, ADRB1 | HSD11B1 129/4885NPC1 750/4885PDE4B 81/4885 |
| US-20120108624-A1 | TREATMENT OF DYSKINESIA RELATED DISORDERS | PARK7, ACHE, SNCA | HSD11B1 1979/4885NPC1 2122/4885PDE4B 85/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.